Prediction: Energy Transfer's Stock Still Looks Like a Buy
Energy Transfer has kicked off the year with impressive momentum and a raised outlook. This article breaks down why t...
When Is An Index Fund Priced
Index funds are priced at the end of the trading day based on net asset value and intraday adjustments. This intro explains the timing and what to watch.
15,016 articles
Revealing Facts About Matthew Perry: Financial Lessons
Public interest in Matthew Perry's passing sparked conversations beyond celebrity trivia. This article dives into rev...
Beyond Meat Trading Near: Is It Finally Time to Buy?
Beyond Meat trading near its lows has investors weighing a potential turnaround. This article breaks down what to wat...
Daré (Dare) 2026 Earnings: A Comprehensive Investor Guide
As Daré gears up to discuss Q1 2026 results, investors will scrutinize cash runway, pipeline milestones, and strategi...
Occidental Petroleum Stock This Year Leads Oil Stocks
Occidental Petroleum is leading oil peers in early 2026, with a solid YTD run that outpaces ConocoPhillips and Diamon...
Workers Face Growing 'Automation' Anxiety as AI Surges
Tech firms push AI deeper into operations even as layoffs rise. The result is growing anxiety among workers about job...
FinVolution (FINV) 2026 Earnings: Outlook, Risks, and Opportunities
A practical guide to understanding finvolution (finv) 2026 earnings, what to watch in the Q1 transcript, and how to p...
U.S. Economy Slows 2026: 3 Dividend ETFs That Hold Up
As signs point to a softer economy in 2026, dividend-focused ETFs can provide ballast. This guide identifies three re...
Adrián Beltré Leaves Room for Wander Franco: MLB Decision
When prominent athletes face controversy, the financial implications go beyond contracts. This piece explores how Adr...
FedEx Following FedEx Freight: Is Now a Buy Opportunity?
FedEx recently spun off its FedEx Freight unit, creating two focused companies. This article explains what that move ...
CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
62-Year-Old Locks $2,400 Monthly to Dodge 2032 Cut
A 62-year-old plans to claim early Social Security to lock in $2,400 monthly, hoping to outpace a coming 2032 reducti...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status